推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

CLINICAL CANCER RESEARCH

2023年12月最新中科院分区表数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 CLIN CANCER RES最新评论:你的送审了吗? (2023-12-01)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中科院分区:   是否OA期刊:   结果排序:

同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


CLINICAL CANCER RESEARCH期刊基本信息Hello,您是该期刊的第171112位访客

基本信息 登录收藏
期刊名字CLINICAL CANCER RESEARCHCLINICAL CANCER RESEARCH

CLIN CANCER RES
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
9.3
51人评分
我要评分

声誉
9.9

影响力
8.7

速度
9.6

期刊ISSN1078-0432
微信扫码收藏此期刊
E-ISSN1557-3265
2022-2023最新影响因子
(数据来源于搜索引擎)
11.5 点击查看影响因子趋势图
实时影响因子 截止2023年12月27日:9.064
2022-2023自引率1.70%点击查看自引率趋势图
五年影响因子12.5
h-index 292
CiteScore
CiteScoreSJRSNIPCiteScore排名
21.804.6032.156
学科分区排名百分位
大类:Medicine
小类:General Medicine
Q116 / 830

期刊简介Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease.
期刊官方网站http://clincancerres.aacrjournals.org/
期刊投稿网址http://ccr.msubmit.net/cgi-bin/main.plex
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足CLINICAL CANCER RESEARCH的语言要求,还能让CLINICAL CANCER RESEARCH编辑和审稿人得到更好的审稿体验,让稿件最大限度地被CLINICAL CANCER RESEARCH编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问No
通讯方式AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404
出版商American Association for Cancer Research Inc.
涉及的研究方向医学-肿瘤学
出版国家或地区UNITED STATES
出版语言English
出版周期Semimonthly
出版年份1995
年文章数 491点击查看年文章数趋势图
Gold OA文章占比18.13%
研究类文章占比:
文章 ÷(文章 + 综述)
93.69%
WOS期刊SCI分区
2022-2023年最新版
WOS分区等级:1区

按学科分区JIF分区JIF排名JIF百分位
学科:ONCOLOGY
类别:SCIE
Q122/241
中科院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中科院SCI期刊分区
2023年12月最新升级版
点击查看中科院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 2区1区2区
ONCOLOGY
肿瘤学
4区3区1区
中科院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 3区1区4区
ONCOLOGY
肿瘤学
3区4区1区
中科院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 2区1区4区
ONCOLOGY
肿瘤学
3区4区1区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1078-0432%5BISSN%5D
平均审稿速度网友分享经验:
平均2.1月
平均录用比例网友分享经验:
约30%
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在CLINICAL CANCER RESEARCH顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 CLINICAL CANCER RESEARCH期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 CLINICAL CANCER RESEARCH中科院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
CLINICAL CANCER RESEARCH上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中科院SCI期刊分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发表论文
  • 中科院SCI期刊分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    Nature Reviews Clinical Oncology12775.50
    NATURE REVIEWS CANCER39696.70
    LANCET ONCOLOGY27462.00
    ANNALS OF ONCOLOGY21063.00
    CANCER CELL29552.90
    JOURNAL OF CLINICAL ONCOLOGY49439.60
    SEMINARS IN CANCER BIOLOGY13420.00
    CANCER TREATMENT REVIEWS11620.70
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH6720.70
    中科院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE596635
    BIOMATERIALS510073
    BIOMEDICINE & PHARMACOTHERAPY457837
    Journal of Materials Chemistry B456170
    Frontiers in Pharmacology445174
    Frontiers in Immunology415616
    COLLOIDS AND SURFACES B-BIOINTERFACES401344
    JOURNAL OF ETHNOPHARMACOLOGY400540
    Frontiers in Oncology380076
    Acta Biomaterialia372353
  •  

    CLINICAL CANCER RESEARCH CLINICAL CANCER RESEARCH
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

    Author: Chen, Wei; Shi, Hui; Liu, Zhuojun; Yang, Fan; Liu, Jia; Zhang, Leqiang; Wu, Yajin; Xia, Yuanshi; Ou, Yuxuan; Li, Ruiting; Zhang, Ting; Zhang, Jiecheng; Ke, Xiaoyan; Hu, Kai; Yu, Jian
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 8, pp. 1484-1495. DOI: 10.1158/1078-0432.CCR-22-2924
        PubMed      DOI
    2.Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies

    Author: Zhai, Yifan; Tang, Qiuqiong; Fang, Douglas D.; Deng, Jing; Zhang, Kaixiang; Wang, Qixin; Yin, Yan; Fu, Chengcheng; Xue, Sheng -Li; Li, Na; Zhou, Feng; Yang, Dajun
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 183-196. DOI: 10.1158/1078-0432.CCR-22-0978
        PubMed      DOI
    3.Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer

    Author: Peng, Ke; Zhang, Feifei; Wang, Yichen; Sahgal, Pranshu; Li, Tianxia; Zhou, Jin; Liang, Xiaoyan; Zhang, Yanxi; Sethi, Nilay; Liu, Tianshu; Zhang, Haisheng; Bass, Adam J.
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 197-208. DOI: 10.1158/1078-0432.CCR-22-1609
        PubMed      DOI
    4.Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes

    Author: Bai, Jiwei; Shi, Jianxin; Zhang, Yazhuo; Li, Chuzhong; Xiong, Yujia; Koka, Hela; Wang, Difei; Zhang, Tongwu; Song, Lei; Luo, Wen; Zhu, Bin; Hicks, Belynda; Hutchinson, Amy; Kirk, Erin; Troester, Melissa A.; Li, Mingxuan; Shen, Yutao; Ma, Tianshun; Wang, Junmei; Liu, Xing; Wang, Shuai; Gui, Songbai; McMaster, Mary L.; Chanock, Stephen J.; Parry, Dilys M.; Goldstein, Alisa M.; Yang, Xiaohong R.
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 261-270. DOI: 10.1158/1078-0432.CCR-22-1865
        PubMed      DOI
    5.Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma

    Author: Wang, Jun; Guo, Wei; Wang, Xiaofang; Tang, Xiaodong; Sun, Xin; Ren, Tingting
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 3, pp. 659-666. DOI: 10.1158/1078-0432.CCR-22-2682
        PubMed      DOI
    6.Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect

    Author: Luo, Ren; Onyshchenko, Kateryna; Wang, Liqun; Gaedicke, Simone; Grosu, Anca-Ligia; Firat, Elke; Niedermann, Gabriele
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 3, pp. 667-683. DOI: 10.1158/1078-0432.CCR-22-1591
        PubMed      DOI
    7.First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001

    Author: Zhou, Yan; Yang, Qingcheng; Dong, Yang; Ji, Tong; Zhang, Bing; Yang, Cheng; Zheng, Shuier; Tang, Lina; Zhou, Chenliang; Qian, Guowei; Huang, Yujing; Yu, Wenxi; Li, Hongtao; Wang, Yonggang; He, Aina; Shen, Zan; Bao, Qiyuan; Hua, Yingqi; Bai, Hongyu; Zhao, Jiayi; Li, Xiaoyi; Dai, Xiangrong; Zhang, Jianjun; Hu, Haiyan; Yao, Yang
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 764-774. DOI: 10.1158/1078-0432.CCR-22-2470
        PubMed      DOI
    8.Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

    Author: Song, Xuyang; Kelley, Robin Kate; Khan, Anis A.; Standifer, Nathan; Zhou, Diansong; Lim, KyoungSoo; Krishna, Rajesh; Liu, Lu; Wang, Kun; McCoon, Patricia; Negro, Alejandra; He, Philip; Gibbs, Megan; Kurland, John F.; Abou-Alfa, Ghassan K.
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 754-763. DOI: 10.1158/1078-0432.CCR-22-1983
        PubMed      DOI
    9.Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

    Author: Chen, Huang; Zhou, Wenbo; Bian, Aiwu; Zhang, Qiansen; Miao, Ying; Yin, Xuan; Ye, Jiangnan; Xu, Shifen; Ti, Chaowen; Sun, Zhenliang; Zheng, Jianghua; Chen, Yihua; Liu, Mingyao; Yi, Zhengfang
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 815-830. DOI: 10.1158/1078-0432.CCR-22-0997
        PubMed      DOI
    10.An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas

    Author: Lu, Xiaofan; Vano, Yann; Helleux, Alexandra; Su, Xiaoping; Lindner, Veronique; Davidson, Guillaume; Mouawad, Roger; Spano, Jean-Philippe; Roupre, Morgan; Elaidi, Reza; Comperat, Eva; Verkarre, Virginie; Sun, Chengming; Chevreau, Christine; Bennamoun, Mostefa; Lang, Herve; Tricard, Thibault; Cheng, Wenxuan; Xu, Li; Davidson, Irwin; Yan, Fangrong; Fridman, Wolf Herman; Sautes-Fridman, Catherine; Oudard, Stephane; Malouf, Gabriel G.
    Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 7, pp. 1279-1291. DOI: 10.1158/1078-0432.CCR-22-2133
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    LANCET700133.20
    NEW ENGLAND JOURNAL OF MEDICINE933134.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62245.40
    NATURE REVIEWS DRUG DISCOVERY289123.80
    BMJ-British Medical Journal015.30
    BMJ-British Medical Journal015.30
    NATURE REVIEWS IMMUNOLOGY35183.00
    NATURE MEDICINE497107.50
    Nature Reviews Disease Primers4860.90
    同分区等级的其他期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    LANCET700133.20
    NEW ENGLAND JOURNAL OF MEDICINE933134.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62245.40
    NATURE REVIEWS DRUG DISCOVERY289123.80
    NATURE REVIEWS MOLECULAR CELL BIOLOGY386164.40
    BMJ-British Medical Journal015.30
    BMJ-British Medical Journal015.30
    NATURE REVIEWS IMMUNOLOGY35183.00
    NATURE REVIEWS MICROBIOLOGY25060.20


以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

    同领域作者分享投稿经验:共228条 (包含回复)

我来分享

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海分公司    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960

    增值电信业务经营许可证:沪B2-20211595

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室

    United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451